Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from February 15, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 16, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$121.41 Published $133.55 Target $111.38 Window close $125.14 Peak
$118.00 – $123.00Entry zone — fair-value band
$121.41Published — price the day we called it
$133.55Target — the price the thesis aimed for
$125.14Peak — highest point inside the window, not a realized return
$111.38Window close — end-of-window price, context only

What happened

Partial

Reached 31% of the predicted growth at its peak, without hitting the target.

Peak price
$125.14
peak on February 25, 2026 — not a realized return
Peak gain
+3.1%
peak, from the publication price
Window close
$111.38
end-of-window price, context only
Days to target
—
Window
February 15, 2026 – May 16, 2026

The thesis — published February 15, 2026

Predicted growth
+10%
over the measurement window
Target price
$133.55
the price the thesis aimed for
Entry zone
$118.00 – $123.00
the fair-value band we waited for
Price at publication
$121.41
published February 15, 2026
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck is a lower-risk choice for the next few months because a recent FDA OK for a new use of KEYTRUDA (ovarian cancer) improves how investors see the company. In uncertain markets it tends to move less wildly than tech, so it can steady a portfolio. Look to buy near the stated price range and watch trading activity closely for signs of weakening demand.

Primary drivers

  • New FDA approval expands KEYTRUDA use and improves near-term outlook
  • Healthcare stocks can do better when investors seek safer options
  • Big cancer drug lineup keeps investors focused on company updates
  • Investors who want income may favor it when markets get risky

How it played out

MRK: target was not reached

Lyra published MRK at $121.41 on 2026-02-15 with 10% expected growth. The target was $133.55. The thesis pointed to a new FDA approval expanding KEYTRUDA use, steadier healthcare demand in uncertain markets, the cancer drug lineup, and income-focused investor interest.

Inside the window, MRK peaked at $125.14 on 2026-02-25, a 3.1% gain. It never reached the target. By 2026-05-16, it ended at $111.38. The thesis only partly played out: there was an early move higher, but it stayed below the target and finished under the publication price.

What happened during the window

On 2026-04-30, Merck reported first-quarter sales of $16.29 billion and raised full-year guidance. The report also said KEYTRUDA sales rose 12% in the quarter. These were company results reported during the measurement window, not stated causes of the stock move.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals